Kijanka G - Search Results

1

Fate of Multimeric Oligomers, Submicron, and Micron Size Aggregates of Monoclonal Antibodies Upon Subcutaneous Injection in Mice.

Kijanka G, Bee JS, Bishop SM, Que I, Löwik C, Jiskoot W. Kijanka G, et al. J Pharm Sci. 2016 May;105(5):1693-1704. doi: 10.1016/j.xphs.2016.02.034. Epub 2016 Apr 1. J Pharm Sci. 2016. PMID: 27044942

2

Submicron Size Particles of a Murine Monoclonal Antibody Are More Immunogenic Than Soluble Oligomers or Micron Size Particles Upon Subcutaneous Administration in Mice.

Kijanka G, Bee JS, Korman SA, Wu Y, Roskos LK, Schenerman MA, Slütter B, Jiskoot W. Kijanka G, et al. J Pharm Sci. 2018 Nov;107(11):2847-2859. doi: 10.1016/j.xphs.2018.06.029. Epub 2018 Jul 10. J Pharm Sci. 2018. PMID: 30003898

3

Monoclonal Antibody Dimers Induced by Low pH, Heat, or Light Exposure Are Not Immunogenic Upon Subcutaneous Administration in a Mouse Model.

Kijanka G, Bee JS, Schenerman MA, Korman SA, Wu Y, Slütter B, Jiskoot W. Kijanka G, et al. J Pharm Sci. 2020 Jan;109(1):730-738. doi: 10.1016/j.xphs.2019.04.021. Epub 2019 Apr 25. J Pharm Sci. 2020. PMID: 31029572

4

Development of a transgenic mouse model to study the immunogenicity of recombinant human insulin.

Torosantucci R, Brinks V, Kijanka G, Halim LA, Sauerborn M, Schellekens H, Jiskoot W. Torosantucci R, et al. Among authors: kijanka g. J Pharm Sci. 2014 May;103(5):1367-74. doi: 10.1002/jps.23935. Epub 2014 Mar 11. J Pharm Sci. 2014. PMID: 24619587

5

Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges.

Jiskoot W, Kijanka G, Randolph TW, Carpenter JF, Koulov AV, Mahler HC, Joubert MK, Jawa V, Narhi LO. Jiskoot W, et al. Among authors: kijanka g. J Pharm Sci. 2016 May;105(5):1567-1575. doi: 10.1016/j.xphs.2016.02.031. Epub 2016 Apr 1. J Pharm Sci. 2016. PMID: 27044944 Free PMC article. Review.

6

Effect of treatment regimen on the immunogenicity of human interferon Beta in immune tolerant mice.

Kijanka G, Jiskoot W, Schellekens H, Brinks V. Kijanka G, et al. Pharm Res. 2013 Jun;30(6):1553-60. doi: 10.1007/s11095-013-0992-9. Epub 2013 Jan 30. Pharm Res. 2013. PMID: 23361590

7

Antibody response against Betaferon® in immune tolerant mice: involvement of marginal zone B-cells and CD4+ T-cells and apparent lack of immunological memory.

Sauerborn M, van Beers MM, Jiskoot W, Kijanka GM, Boon L, Schellekens H, Brinks V. Sauerborn M, et al. J Clin Immunol. 2013 Jan;33(1):255-63. doi: 10.1007/s10875-012-9783-z. Epub 2012 Sep 4. J Clin Immunol. 2013. PMID: 22945588

8

Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins.

Hamuro L, Kijanka G, Kinderman F, Kropshofer H, Bu DX, Zepeda M, Jawa V. Hamuro L, et al. Among authors: kijanka g. J Pharm Sci. 2017 Oct;106(10):2946-2954. doi: 10.1016/j.xphs.2017.05.030. Epub 2017 May 31. J Pharm Sci. 2017. PMID: 28576695 Review.

9

Influence of aggregation and route of injection on the biodistribution of mouse serum albumin.

Kijanka G, Prokopowicz M, Schellekens H, Brinks V. Kijanka G, et al. PLoS One. 2014 Jan 22;9(1):e85281. doi: 10.1371/journal.pone.0085281. eCollection 2014. PLoS One. 2014. PMID: 24465523 Free PMC article.

10

Development of ADA against recombinant human interferon beta in immune tolerant mice requires rapid recruitment of CD4⁺ T cells, induces formation of germinal centers but lacks susceptibility for (most) adjuvants.

Kijanka G, Sauerborn M, Boon L, Schellekens H, Brinks V. Kijanka G, et al. J Pharm Sci. 2015 Feb;104(2):396-406. doi: 10.1002/jps.24170. Epub 2014 Sep 12. J Pharm Sci. 2015. PMID: 25219665

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

40 results

Search Page

Filters